Skip to main content

Compare Stocks

Date Range: 

 NGM BiopharmaceuticalsIGM BiosciencesRevance TherapeuticsAmarinMadrigal Pharmaceuticals
SymbolNASDAQ:NGMNASDAQ:IGMSNASDAQ:RVNCNASDAQ:AMRNNASDAQ:MDGL
Price Information
Current Price$28.58$68.76$29.06$4.38$134.70
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.71.71.71.61.5
Analysis Score3.63.43.53.22.4
Community Score3.42.52.63.12.8
Dividend Score0.00.00.00.00.0
Ownership Score1.72.51.70.82.5
Earnings & Valuation Score0.00.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$39.11$98.88$38.50$10.50$167.60
% Upside from Price Target36.85% upside43.80% upside32.48% upside139.73% upside24.42% upside
Trade Information
Market Cap$2.20 billion$2.20 billion$2.08 billion$1.72 billion$2.23 billion
Beta1.97-1.121.422.581.19
Average Volume255,723195,850429,8576,371,316162,137
Sales & Book Value
Annual Revenue$103.54 millionN/A$410,000.00$429.76 millionN/A
Price / Sales21.26N/A5,069.844.01N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.96 per share$7.88 per share$5.00 per share$1.63 per share$27.00 per share
Price / Book5.76N/A5.812.69N/A
Profitability
Net Income$-42,790,000.00$-43,130,000.00$-159,430,000.00$-22,650,000.00$-83,950,000.00
EPS($0.85)($4.80)($3.67)($0.07)($5.45)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/A36.50N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-91.64%N/A-5,818.87%-2.69%N/A
Return on Equity (ROE)-29.47%-33.30%-85.72%-2.70%-47.64%
Return on Assets (ROA)-25.58%-30.28%-44.85%-1.72%-43.21%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.48%N/AN/A
Current Ratio8.01%13.90%7.07%2.72%6.84%
Quick Ratio8.01%13.90%7.01%2.27%6.84%
Ownership Information
Institutional Ownership Percentage49.56%47.60%74.35%37.78%74.24%
Insider Ownership Percentage50.40%79.34%4.80%2.75%41.89%
Miscellaneous
Employees2101074701,00042
Shares Outstanding77.02 million32.01 million71.53 million393.44 million16.59 million
Next Earnings Date8/11/2021 (Estimated)8/5/2021 (Estimated)8/5/2021 (Estimated)8/3/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Chardan Capital Stick to Their Buy Rating for Madrigal Pharmaceuticals IncChardan Capital Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
investing.com - May 10 at 4:04 PM
Madrigal Pharmaceuticals (NASDAQ:MDGL) Announces Quarterly  Earnings ResultsMadrigal Pharmaceuticals (NASDAQ:MDGL) Announces Quarterly Earnings Results
americanbankingnews.com - May 9 at 1:16 PM
Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals IncLeerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
investing.com - May 9 at 9:24 AM
-$3.75 EPS Expected for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) This Quarter-$3.75 EPS Expected for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) This Quarter
americanbankingnews.com - May 8 at 9:14 AM
Madrigal: Q1 Earnings SnapshotMadrigal: Q1 Earnings Snapshot
sfgate.com - May 6 at 11:53 AM
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights
finance.yahoo.com - May 6 at 11:53 AM
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High at $137.81Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High at $137.81
americanbankingnews.com - April 27 at 1:38 PM
Were Keeping An Eye On Madrigal Pharmaceuticals (NASDAQ:MDGL) Cash Burn RateWe're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
nasdaq.com - April 27 at 8:41 AM
Zacks: Analysts Expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to Announce -$3.78 Earnings Per ShareZacks: Analysts Expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to Announce -$3.78 Earnings Per Share
americanbankingnews.com - April 21 at 12:14 AM
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up to $121.19Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up to $121.19
americanbankingnews.com - April 20 at 12:50 PM
MDGL Makes Notable Cross Below Critical Moving AverageMDGL Makes Notable Cross Below Critical Moving Average
nasdaq.com - March 23 at 5:42 PM
Madrigal Pharmaceuticals, Inc.(MDGL)Madrigal Pharmaceuticals, Inc.(MDGL)
fool.com - March 11 at 9:27 AM
Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL)Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
smarteranalyst.com - March 2 at 12:35 PM
Madrigal: 4Q Earnings Snapshot | Raleigh News & ObserverMadrigal: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 25 at 7:22 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
Market insanity hits MicroCapMarket insanity hits MicroCap
fxstreet.com - February 5 at 10:14 AM
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomets Spin-Off, IPO Deluge Hits StreetThe Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
msn.com - February 5 at 10:14 AM
Is MDGL A Good Stock To Buy Now?Is MDGL A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 12:30 AM
Heres Why Were Not Too Worried About Madrigal Pharmaceuticals (NASDAQ:MDGL) Cash Burn SituationHere's Why We're Not Too Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
finance.yahoo.com - November 24 at 12:09 PM
MDGL Nov 2020 110.000 callMDGL Nov 2020 110.000 call
uk.finance.yahoo.com - November 21 at 8:03 PM
MDGL Nov 2020 80.000 callMDGL Nov 2020 80.000 call
uk.finance.yahoo.com - November 20 at 10:43 PM
MDGL Nov 2020 155.000 callMDGL Nov 2020 155.000 call
uk.finance.yahoo.com - November 20 at 5:41 PM
Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- SlideshowMadrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
seekingalpha.com - November 19 at 8:15 PM
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The ...Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The ...
apnews.com - November 14 at 1:45 PM
DateCompanyBrokerageAction
3/11/2021NGM BiopharmaceuticalsRaymond JamesBoost Price Target
3/11/2021NGM BiopharmaceuticalsChardan CapitalBoost Price Target
2/9/2021NGM BiopharmaceuticalsThe Goldman Sachs GroupBoost Price Target
1/5/2021NGM BiopharmaceuticalsStifel NicolausReiterated Rating
12/21/2020NGM BiopharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/21/2020NGM BiopharmaceuticalsSmith Barney CitigroupBoost Price Target
12/14/2020NGM BiopharmaceuticalsB. RileyBoost Price Target
7/30/2020NGM BiopharmaceuticalsPiper SandlerInitiated Coverage
6/4/2020NGM BiopharmaceuticalsBMO Capital MarketsInitiated Coverage
3/23/2020NGM BiopharmaceuticalsCowenReiterated Rating
3/31/2021IGM BiosciencesTruistBoost Price Target
3/31/2021IGM BiosciencesHC WainwrightReiterated Rating
1/29/2021IGM BiosciencesRoyal Bank of CanadaInitiated Coverage
12/22/2020IGM BiosciencesWedbushDowngrade
7/16/2020IGM BiosciencesRobert W. BairdInitiated Coverage
5/28/2020IGM BiosciencesSunTrust BanksInitiated Coverage
3/12/2020IGM BiosciencesWolfe ResearchInitiated Coverage
1/6/2020IGM BiosciencesPiper Jaffray CompaniesBoost Price Target
10/14/2019IGM BiosciencesJefferies Financial GroupInitiated Coverage
10/14/2019IGM BiosciencesGuggenheimInitiated Coverage
5/11/2021Revance TherapeuticsMizuhoLower Price Target
4/14/2021Revance TherapeuticsNeedham & Company LLCReiterated Rating
10/26/2020Revance TherapeuticsBarclaysBoost Price Target
3/27/2020Revance TherapeuticsWilliam BlairReiterated Rating
2/1/2021AmarinSVB LeerinkBoost Price Target
9/29/2020AmarinJPMorgan Chase & Co.Initiated Coverage
9/8/2020AmarinCantor FitzgeraldLower Price Target
6/3/2020AmarinOppenheimerReiterated Rating
5/5/2020AmarinNorthland SecuritiesInitiated Coverage
5/4/2020AmarinAegisBoost Price Target
11/23/2020Madrigal PharmaceuticalsEvercore ISIReiterated Rating
11/12/2020Madrigal PharmaceuticalsCanaccord GenuityLower Price Target
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.